Back to company

Novo Nordisk Denmark A/S: Financial statements 2021

CVR: 38180045

Novo Nordisk Denmark A/S (CVR 38180045) has filed annual accounts for 2021. In 2021, the company reported revenue of DKK 373,940,044 and a net result of DKK 21,405,179 compared with DKK 21,277,960 the year before. That is an increase of 13.3% compared with the year before. The profit margin was 5.7%. Equity amounted to DKK 36,992,544. The solvency ratio was 13.1%. The company had 176 employees in the financial year.

Revenue
373,940,044 kr.
Gross Profit
311,890,965 kr.
Profit/Loss
21,405,179 kr.
Equity
36,992,544 kr.
Total Assets
283,420,395 kr.
Employees
176

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2021373.9 mio.311.9 mio.21.4 mio.37 mio.176
2020330.1 mio.276.1 mio.21.3 mio.36.6 mio.152
2019363.9 mio.134.9 mio.5.3 mio.15.3 mio.65
2018341.9 mio.119.2 mio.4.2 mio.10.1 mio.69

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Novo Nordisk Denmark A/S

Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.

Try the lead list generator

Events in 2021

Novo Nordisk Denmark A/S: The 2020 annual report is outJun 15, 2021

Novo Nordisk Denmark A/S has published its annual report for 2020. Revenue came to DKK 330,145,351, and the net result was DKK 21,277,960.

Novo Nordisk Denmark A/S appoints new auditorApr 15, 2021

As of April 15, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novo Nordisk Denmark A/S.

Auditor steps down at Novo Nordisk Denmark A/SApr 15, 2021

As of April 15, 2021, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Novo Nordisk Denmark A/S.

About Novo Nordisk Denmark A/S

Novo Nordisk Denmark A/S is a Danish company of the type Aktieselskab based in København S, founded in 2016. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Novo Nordisk Region Europe Pharmaceuticals A/S. The management consists of Mads Wilhelm Øckenholt Larsen. The company is owned by NOVO NORDISK REGION EUROPE A/S. The company has 81 employees. In 2025, the company reported revenue of DKK 2,504,841,000 and a net result of DKK 118,803,000 compared with DKK 86,129,000 the year before. Equity amounted to DKK 134,570,000.

Other financial years